Effects of transcranial direct-current stimulation over the Supplementary Motor Area on motor control and inhibition

Summary

We are studying how a non-invasive, low electrical current applied through the scalp affects the part of the brain that helps start and stop movements. During one visit (about 1.5-2 hours) at Foothills Medical Centre, you will have a brain scan (MRI), receive 20 minutes of gentle transcranial direct-current stimulation (tDCS), and do simple computer button-press tasks. We will compare brain activity before, during, and after the stimulation. What we learn may help design future, non-invasive treatments for movement and tic disorders such as Tourette syndrome. Participants will receive $45 for their time.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 65

Accepts healthy participants: Yes

Inclusion criteria:

You may be able to take part if you:

1) Are 18 years or older.
2) Are healthy, with no history of neurological or psychiatric disorders.
3) Are right-handed.
4) Speak and understand English.

Exclusion criteria:

You cannot participate if you:

1) Have any metal in your head or body (such as implants, clips, or pacemakers).
2) Have a diagnosis of epilepsy, seizures, heart disease or neurological Have been diagnosed with a neurological or psychiatric condition that affects movement (Parkinson’s disease, Tourette syndrome, etc.).
3) Have a history of traumatic brain injury, learning disability, or dyslexia.
4) Have a severe vision or hearing problem that prevents you from doing computer tasks.
5) Feel very uncomfortable in small spaces (such as during an MRI scan).

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Davide Martino, MD, PhD (Principal Investigator) Cumming School of Medicine, University of Calgary Health Sciences Centre 3330 Hospital Drive NW, Calgary, AB, CANADA T2N 4N1 P: 403.210.8726 F: 403.210.9149 E: davide.martino@ucalgary.ca

Principal investigator:

Davide Martino

Clinical trial:

No

REB-ID:

REB25-1147